Status:

COMPLETED

Influence of Escitalopram on Fear Conditioning

Lead Sponsor:

Massachusetts General Hospital

Collaborating Sponsors:

Forest Laboratories

Conditions:

Fear Conditioning

Eligibility:

All Genders

18-75 years

Phase:

PHASE4

Brief Summary

The purpose of the study is to learn how differences in learning under mildly-stressful circumstances may be changed by taking an antidepressant medication. This medication is called Lexapro (Escitalo...

Eligibility Criteria

Inclusion

  • Male or female outpatients 18 to 75 years of age
  • Must have no current DSM-IV Axis I diagnosis as measured by the SCID (Structured Clinical Interview for DSM-IV-TR axis 1 disorders) with a trained study investigator. Past history of anxiety disorders, major depressive episodes or substance abuse disorders at least six months prior to baseline are not exclusionary.

Exclusion

  • Patients will be excluded from entry into the study for current serious medical conditions or other conditions deemed likely to result in surgery or hospitalization.
  • Patients with a history of trauma resulting in head injury related seizures, or with epilepsy (except a prior history of febrile seizures of infancy which are not exclusionary).
  • Pregnant or lactating women or those of childbearing potential not using medically accepted forms of contraception will be excluded.
  • Concurrent use of other antidepressants, benzodiazepines or antipsychotic medications.
  • Patients with a history of hypersensitivity to escitalopram are excluded.
  • Individuals must have discontinued MAO inhibitors more than 14 days before starting study drug.
  • Additional contraindicated drugs during the study are pimozide, furazolidine, isocarboxazid, lazabemide, and St. John's Wort.
  • Participants meeting DSM-IV or SCID criteria for a substance use disorder in the last six months other than nicotine dependence and those with a positive toxicology screen at baseline consistent with evidence of current substance abuse or dependence as determined by clinical interview.
  • A lifetime history of Bipolar or any psychotic disorder is excluded.
  • Current claustrophobia is exclusionary.
  • Patients currently taking any narcotic will be excluded.

Key Trial Info

Start Date :

October 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2011

Estimated Enrollment :

65 Patients enrolled

Trial Details

Trial ID

NCT01398514

Start Date

October 1 2008

End Date

June 1 2011

Last Update

June 11 2014

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.